Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Figures

• 

  Figure 1. The cumulative incidence of any DM for NHL patients without preexisting DM treated with steroid-containing immunochemotherapy compared with matched comparators without preexisting DM. Aalen-Johansen estimator treating death, relapse, and NHL diagnosis (in comparators) as competing events. P value from Gray's test. The y-axis is limited to 10%.

• 

  Figure 2. The incidences rates (red for matched comparators; blue for NHL patients) of new-onset diabetes mellitus per 1000 person years and the incidence rate ratio (IRR; green) between patients and matched comparators >10 years from start of lymphoma treatment (index date). The dotted black line shows an IRR of 1.0 for reference.

• 

  Figure 3. The cumulative risk of any insulin prescription for NHL patients with preexisting non–insulin-dependent DM treated with steroid-containing immunochemotherapy compared with matched comparators with preexisting non–insulin-dependent DM. Aalen-Johansen estimator treating death, relapse, and NHL diagnosis (in comparators) as competing events. P value from Gray's test.

• 

  Figure 4. The cumulative risk of new-onset CVD for NHL patients with preexisting DM treated with steroid- and anthracycline-containing immunochemotherapy compared with matched comparators with preexisting DM and matched comparators without DM. Aalen-Johansen estimator treating death, relapse, and NHL diagnosis (in comparators) as competing events. P value from Gray's test.

• 

  Figure 5. The incidences rates (red for matched comparators; blue for NHL patients with preexisting DM treated with steroid- and anthracycline-containing immunochemotherapy) of new-onset CVD per 1000 person years and the incidence rate ratio (IRR; green) between patients and matched comparators >10 years from start of lymphoma treatment (index date). The dotted black line shows an IRR of 1.0 for reference.